Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Constant Currency Growth in Rest of World (% cc) by Quarter
Constant Currency Growth in Rest of World (% cc) (%)
Novartis Constant Currency Growth in Rest of World (% cc): 68.0% in Q3 2026, up 50.0 pts from a year earlier.
Latest, Q3 2026
68.0%
Period ended Sep 30, 2026
Change on a year earlier
+50.0 pts
18.0% in Q3 2025
History
12 quarters
Since Q1 2023
Sources
12
Documents cited below
Where the Q3 2026 figure comes from
“|| Pluvicto | Oncology | PSMA-positive mAPMN/S, mAPMR patients post-ARPI, pre- and post-Taxane | 502 | 9 | 172 | 65 | 68 | 674 | 20 | 20”
Source: Novartis Form 6-K (0001114448-26-000014) ↗
Reported in Form 6-K & Form 20-F.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Constant Currency Growth in Rest of World (% cc) (%) | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 68.0% | +50.0 pts | Novartis Form 6-K (0001114448-26-000014) ↗ |
| Q2 2026 | Jun 30, 2026 | 62.0% | -18.0 pts | Novartis Form 6-K (0001114448-26-000012) ↗ |
| Q1 2026 | Mar 31, 2026 | 48.0% | -157.0 pts | Novartis Form 6-K (0001114448-26-000010) ↗ |
| Q4 2025 | Dec 31, 2025 | 52.0% | -168.0 pts | Novartis Form 6-K (0001114448-26-000007) ↗ |
| Q3 2025 | Sep 30, 2025 | 18.0% | – | Novartis Form 6-K (0001114448-25-000003) ↗ |
| Q2 2025 | Jun 30, 2025 | 80.0% | -194.0 pts | Novartis Form 6-K (0001370368-25-000012) ↗ |
| Q1 2025 | Mar 31, 2025 | 205.0% | – | Novartis Form 6-K (0001370368-25-000010) ↗ |
| Q4 2024 | Dec 31, 2024 | 220.0% | +80.0 pts | Novartis Form 6-K (0001370368-25-000007) ↗ |
| Q2 2024 | Jun 30, 2024 | 274.0% | – | Novartis Form 6-K (0001370368-24-000019) ↗ |
| Q4 2023 | Dec 31, 2023 | 140.0% | – | Novartis Form 6-K (0001370368-24-000007) ↗ |
| Q3 2023 | Sep 30, 2023 | 165.0% | – | Novartis Form 6-K (0001370368-23-000068) ↗ |
| Q1 2023 | Mar 31, 2023 | 242.0% | – | Novartis Form 6-K (0001370368-23-000046) ↗ |
Cite this data
StockData. (2026). Novartis Constant Currency Growth in Rest of World (% cc) (%), quarterly Q1 2023–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-pluvicto-row-yoy-cc-pct
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.